Sangamo Therapeutics Inc
NASDAQ:SGMO

Watchlist Manager
Sangamo Therapeutics Inc Logo
Sangamo Therapeutics Inc
NASDAQ:SGMO
Watchlist
Price: 2.42 USD -2.02% Market Closed
Market Cap: 504.9m USD
Have any thoughts about
Sangamo Therapeutics Inc?
Write Note

Sangamo Therapeutics Inc
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sangamo Therapeutics Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Sangamo Therapeutics Inc
NASDAQ:SGMO
EPS (Diluted)
$0
CAGR 3-Years
12%
CAGR 5-Years
4%
CAGR 10-Years
-6%
Abbvie Inc
NYSE:ABBV
EPS (Diluted)
$2
CAGR 3-Years
-12%
CAGR 5-Years
6%
CAGR 10-Years
2%
Gilead Sciences Inc
NASDAQ:GILD
EPS (Diluted)
$0
CAGR 3-Years
-75%
CAGR 5-Years
-47%
CAGR 10-Years
-34%
Amgen Inc
NASDAQ:AMGN
EPS (Diluted)
$7
CAGR 3-Years
-7%
CAGR 5-Years
-10%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
EPS (Diluted)
-$1
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
EPS (Diluted)
$40
CAGR 3-Years
-13%
CAGR 5-Years
16%
CAGR 10-Years
30%
No Stocks Found

Sangamo Therapeutics Inc
Glance View

Market Cap
504.9m USD
Industry
Biotechnology

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Brisbane California, California and currently employs 431 full-time employees. The company went IPO on 2000-04-06. The firm focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, its ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD); TX200, its wholly owned Chimeric Antigen Receptor (CAR) engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.

SGMO Intrinsic Value
2.49 USD
Undervaluation 3%
Intrinsic Value
Price

See Also

What is Sangamo Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-0.9 USD

Based on the financial report for Sep 30, 2024, Sangamo Therapeutics Inc's EPS (Diluted) amounts to -0.9 USD.

What is Sangamo Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-6%

Over the last year, the EPS (Diluted) growth was 39%. The average annual EPS (Diluted) growth rates for Sangamo Therapeutics Inc have been 12% over the past three years , 4% over the past five years , and -6% over the past ten years .

Back to Top